The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 04, 2025

Filed:

Oct. 29, 2020
Applicant:

Digmbio. Inc., Gyeonggi-do, KR;

Inventors:

Eunhee Kim, Daejeon, KR;

Changmin Park, Gyeonggi-do, KR;

Sehwan Oh, Gyeonggi-do, KR;

Younghoon Kim, Gyeonggi-do, KR;

Juhee Lee, Gyeonggi-do, KR;

Jaehee Seol, Gyeonggi-do, KR;

Ahram Shim, Gyeonggi-do, KR;

Younggwan Kim, Gyeonggi-do, KR;

Tae-Sung Koo, Gyeonggi-do, KR;

Ki-Hong Jang, Daejeon, KR;

Assignee:

DIGMBIO, INC., Gyeonggi-do, KR;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 217/24 (2006.01); A23L 33/00 (2016.01); A23L 33/10 (2016.01); A61P 27/02 (2006.01); C07D 401/06 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 405/12 (2006.01); C07D 417/12 (2006.01); C07D 451/02 (2006.01);
U.S. Cl.
CPC ...
C07D 217/24 (2013.01); A23L 33/10 (2016.08); A23L 33/40 (2016.08); A61P 27/02 (2018.01); C07D 401/06 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 405/12 (2013.01); C07D 417/12 (2013.01); C07D 451/02 (2013.01); A23V 2002/00 (2013.01);
Abstract

The present invention relates to isoquinolinone derivatives, a method for preparing the same, and a pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1 (PARP-1)-related diseases containing the same as an active ingredient. The isoquinolinone derivatives exhibit an excellent PARP-1 inhibitory effect at a concentration of nanomolar units, and further exhibit an excellent cytoprotective effect (apoptosis inhibitory effect) on ophthalmic diseases or disorders, specifically retinal disorders, and thus can be effectively used as a pharmaceutical composition for preventing or treating PARP-1-related diseases, for example, ophthalmic diseases or disorders, which contains the same as an active ingredient.


Find Patent Forward Citations

Loading…